LifeSci Capital Keeps a Buy Rating on Catalyst Biosciences (CBIO)

By Carrie Williams

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Catalyst Biosciences (CBIOResearch Report), with a price target of $18.00. The company’s shares closed last Thursday at $5.27.

According to, Slutsky is a 2-star analyst with an average return of 0.6% and a 33.3% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics, La Jolla Pharma, and Sierra Oncology.

Catalyst Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $20.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.94 and a one-year low of $3.43. Currently, Catalyst Biosciences has an average volume of 353K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.